Nicorandil
- Generic Name
- Nicorandil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H9N3O4
- CAS Number
- 65141-46-0
- Unique Ingredient Identifier
- 260456HAM0
- Background
Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used ...
- Indication
Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.
- Associated Conditions
- Angina Pectoris
- Associated Therapies
- -
Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
- Conditions
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 402
- Registration Number
- NCT01396395
- Locations
- 🇨🇳
For Locations in, Beijing, China
Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2009-02-20
- Lead Sponsor
- Toujinkai Hospital
- Target Recruit Count
- 129
- Registration Number
- NCT00848562
- Locations
- 🇯🇵
Toujinkai Hospital, Kyoto, Japan
Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
- Conditions
- Interventions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-05-06
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 10
- Registration Number
- NCT00424801
- Locations
- 🇩🇰
Aarhus Hospital, Aarhus, Denmark
Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by a K-ATP
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-11-01
- Target Recruit Count
- 600
- Registration Number
- NCT00212030
- Locations
- 🇯🇵
National Cardiovascular Center, Suita, Osaka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.